Muhammad Umaid Rauf, Philip N Hawkins, Francesco Cappelli, Federico Perfetto, Mattia Zampieri, Alessia Argiro, Aviva Petrie, Steven Law, Aldostefano Porcari, Yousuf Razvi, Joshua Bomsztyk, Sriram Ravichandran, Adam Ioannou, Rishi Patel, Neasa Starr, David F Hutt, Shameem Mahmood, Brendan Wisniowski, Ana Martinez-Naharro, Lucia Venneri, Carol Whelan, Dorota Roczenio, Janet Gilbertson, Helen J Lachmann, Ashutosh D Wechalekar, Claudio Rapezzi, Matteo Serenelli, Paolo Massa, Angelo Giuseppe Caponetti, Alberto Ponziani, Antonella Accietto, Alessandro Giovannetti, Giulia Saturi, Maurizio Sguazzotti, Christian Gagliardi, Elena Biagini, Simone Longhi, Marianna Fontana, Julian D Gillmore
AIMS: To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio cut-offs that reliably exclude monoclonal gammopathy (MG) in chronic kidney disease. METHODS AND RESULTS: A multi-national retrospective study of 3354 patients with suspected or histologically proven cardiac amyloidosis (CA) referred to specialist centres from 2015 to 2021; evaluations included radionuclide bone scintigraphy, serum and urine immunofixation, sFLC assay, eGFR measurement and echocardiography...
March 22, 2023: European Heart Journal